Rosenstock J, Guerci B, Hanefeld M, et al
18 Although treatments are available for diabetes and obesity, there are multiple long-term complications: they remain the leading causes of cardiovascular disease, eye pathology, lower limb amputation and end-stage renal disease
Key Opportunity Areas Opportunities for the development of companion products, which in turn promote long-term adherence to clinical therapy and enhance clinical outcomes in patients receiving GLP-1 Therapy for weight loss and diabetes, are increasing as the adoption of GLP-1 Therapies is becoming more widespread around the world
Product information is for research procurement and identification
NVO appears cheap due to high dependence on semaglutide and lack of near-term pipeline catalysts, justifying its discounted valuation
However, consult your healthcare provider before starting supplementation, especially if you have kidney disease or take other medications
